Catalyst
Slingshot members are tracking this event:
Gilead (GILD) Expects Phase 3 Data Evaluating Bictegravir Single-Tablet Regimen (B/F/TAF) in Combination with Tenofovir Alafenamide (TAF) and Emtricitabine (FTC) for the Treatment of HIV-1 infection in Mid 2017
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| GILD |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
May 30, 2017
Occurred Source:
http://www.gilead.com/news/press-releases/2017/5/gileads-investigational-fixeddose-combination-of-bictegravir-emtricitabine-and-tenofovir-alafenamide-for-the-treatment-of-hiv1-meets-primary-endpoint-in-four-phase-3-studies
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Bictegravir, Tenofovir Alafenamide, Emtricitabine, B/f/taf, Hiv-1 Infection
